Home/Pipeline/Targeted Chemotherapeutics

Targeted Chemotherapeutics

Oncology (unspecified)

Pre-clinicalActive

Key Facts

Indication

Oncology (unspecified)

Phase

Pre-clinical

Status

Active

Company

Theradaptive

About Theradaptive

Theradaptive is a private, preclinical-stage biotech founded in 2015, leveraging a proprietary protein engineering platform to overcome a central challenge in regenerative medicine: the precise and sustained local delivery of therapeutics. By engineering proteins to bind with high affinity to specific materials, the company aims to enhance efficacy and reduce systemic side effects across a range of clinical applications, with a lead focus on spinal fusion and orthopedic repair. The technology has demonstrated superiority over standard of care in multiple preclinical studies conducted at leading institutions, positioning the company to potentially redefine therapeutic delivery in surgery and beyond.

View full company profile

Therapeutic Areas

Orthopedics Vascular Repair Soft Tissue Repair Oncology

Other Oncology (unspecified) Drugs

Drug	Company	Phase	Status
Oncology Vaccine Program	CHAIN Biotech	Pre-clinical	Active
ARX305	NovoCodex Biopharmaceuticals	Phase 1	Active
ARX788	NovoCodex Biopharmaceuticals	Phase 1	Active
Cancer Immunotherapy Nanotherapeutic	Flashpoint Therapeutics	Phase 1	Active
GRWD5769	Greywolf Therapeutics	Phase 1/2	Active
Platform-derived Program(s)	Immuto Scientific	Discovery/Pre-clinical	Active
MBT Oncology Program	Ionic Pharmaceuticals	Pre-clinical	Active
ISB 2301	Ichnos Glenmark Innovation	Preclinical	Active
GRC 65327	Ichnos Glenmark Innovation	Preclinical	Active
Platform-Derived Pipeline	Phinomics	Discovery/Pre-clinical	Active
Lead Small-Molecule Inhibitor	Eris Biotech	Pre-clinical	Active
Orotecan™	Edison Oncology	Phase 1/2a	Active